-
Voxilaprevir is a
hepatitis C
virus (HCV)
nonstructural (NS)
protein 3/4A
protease inhibitor (by Gilead) that is used in
combination with
sofosbuvir and...
- Sofosbuvir/velpatasvir/
voxilaprevir, sold
under the
brand name Vosevi, is a fixed-dose
combination medication for the
treatment of
hepatitis C. It combines...
-
Discovery and
development of NS5A
inhibitors Sofosbuvir/velpatasvir/
voxilaprevir, with more
information about the drug
combination Sofosbuvir/velpatasvir...
-
antiviral mutations are present, 12 w****s of sofosbuvir/velpatasvir/
voxilaprevir (when
certain antiviral mutations are present), or 24 w****s of sofosbuvir...
-
Paritaprevir Simeprevir Sovaprevir† Telaprevir‡
Vaniprevir Vedroprevir§
Voxilaprevir NS5A
inhibitors (–asvir)
Coblopasvir Daclatasvir#
Elbasvir Ledipasvir...
-
Epclusa (sofosbuvir and velpatasvir)
Vosevi (sofosbuvir, velpatasvir, and
voxilaprevir)
Zepatier (elbasvir and grazoprevir)
Mavyret (glecaprevir and pibrentasvir)...
-
combinations were
Epclusa (with velpatasvir) and
Vosevi (with
velpatasvir and
voxilaprevir). For the
fiscal year 2017,
Gilead Sciences reported earnings of US$4...
- J05AP55
Sofosbuvir and
velpatasvir J05AP56 Sofosbuvir,
velpatasvir and
voxilaprevir J05AP57
Glecaprevir and
pibrentasvir J05AP58 Daclatasvir, asunaprevir...
- (5
April 2017). "Efficacy of 8 W****s of Sofosbuvir, Velpatasvir, and
Voxilaprevir in
Patients With
Chronic HCV Infection: 2
Phase 3
Randomized Trials"...
- FDC with
sofosbuvir and on July 17, 2017 in a FDC with
sofosbuvir and
voxilaprevir Pibrentasvir,
approved on
August 3, 2017 in a FDC with
glecaprevir Investigational...
